




Asthma Focus

Key Points



The standard respiratory function test for case detection of chronic obstructive pulmonary disease (COPD) is spirometry. The criterion for diagnosis defined in guidelines is based on the FEV1/FVC ratio forced expiratory ratio (FER) and its severity is based on forced expiratory volume in one second (FEV1) from measurements obtained during maximal forced expiratory manoeuvres. Spirometry is a safe and practical procedure, and when conducted by a trained operator using a spirometer that provides quality feedback, the majority of patients can be coached to provide acceptable and repeatable results. This allows potentially wide application of testing to improve recognition and diagnosis of COPD, such as for case finding in primary care. However, COPD remains substantially under diagnosed in primary care and a major reason for this is underuse of spirometry. The presence of symptoms is not a reliable indicator of disease and diagnosis is often delayed until more severe airflow obstruction is present. Early diagnosis is worthwhile, as it allows risk factors for COPD such as smoking to be addressed promptly and treatment optimised. Paradoxically, investigation of the pathophysiology in COPD has shown that extensive small airway disease exists before it is detectable with conventional spirometric indices, and methods to detect airway disease earlier using the flow-volume curve are discussed.

Diagnosis and early detection of COPD using spirometry

Pathology of chronic obstructive pulmonary disease (COPD)

Relatively early research in the 1950s and 1960s into what was by then recognized as a smoking-related disease focused on pathology, and especially tissue remodeling changes in the airways and lungs. It was observed that throughout the airways there was some element of inflammation, but sub-mucosal mucous gland hyperplasia, epithelial goblet cell hyperplasia and epithelial squamous metaplasia were prominent. The characteristic lung lesion was usually peri-bronchial, centri-lobular parenchymal destruction, termed emphysema). An important conclusion from the detailed pathological analysis of this epoch was that the airway pathological component in COPD was universal and generalized, while emphysema usually developed later, perhaps as a secondary phenomenon and only in some individuals but by no means all. This is different from the diffuse primary pan-acinar emphysema that occurs in the younger-onset alpha-1 anti-trypsin (anti-proteinase) deficiency lung disease, for example.

The next research epoch involved innovative physiological laboratory work in the late 1960s into the 1970s, which defined the obstructive consequences of smoking-related airway disease and the anatomical site of increased airway resistance that ultimately lead to symptoms. From this work, construction of a series of iso-volume pressure-flow curves gave rise to development of the now widely used flow-volume curve, but then without the sophisticated, sensitive and computerized equipment now available, and which we will be discussing later in some detail. However, even by that time and using the relatively crude bellowsbased spirometer, the standard measure for defining airway obstruction had been specified as a reduction in the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC), the forced expiratory ratio (FER); indeed in that regard little has changed over the last fifty years or so, in spite of improved understanding of physiology. Paradoxically, the seminal work of Macklem and others in clinical physiology showed that the first change in spirometry in COPD was actually a reduction in FVC due to air trapping, rather than a change in FEV1 (8). Importantly, they showed that this in turn is caused by fixed small airway narrowing, in airways less than 2 mm internal diameter. To demonstrate this, they used flow-volume studies in patients and volunteers with gases of different densities, and also measured flow resistance in different parts of the airway with retrograde catheters in resected lungs. Normal small airways have low resistance to air flow but this is markedly increased in COPD. In contrast, in asthma the main pattern is one of non-uniformly distributed larger airways obstruction, except in older asthmatics and those that smoke in whom a peripheral distribution of resistive change was common, similar to COPD.



Asthma Focus



Notably, it was shown in this epoch of physiological research, that there could be a great deal of peripheral increase in flow resistance before there was any indication on traditional spirometric measures. Patho-physiological correlation studies followed, indicating that in small airways in COPD there is indeed narrowing due to wall thickening, fibrosis and indeed airway obliteration. This was a new and startling insight, which is now confirmed by more sophisticated methodology, that there can be extensive small airway disease, damage and obliteration before it is detectable with conventional spirometric tests.

Over the years, new physiologic methods were developed to try and pick up these early small airway changes in smokers before overt COPD, defined by the FER emerged. However none was robust or practical enough at the concurrent stage of technological development to be suitable for clinical laboratory or medical office use. Such attempts continue with increasingly sophisticated techniques and this is dealt with in a separate article in this volume; the FER remains the standard. In this article, we will review and discuss how useful in clinical practice this standard measure is, what we know about its pitfalls in clinical application and especially in primary care practice. We will also look anew at how the use of all the information available in the current standard flow-volume curve, which is now routinely obtained at the time of FER measurement but largely ignored, can potentially be harnessed and give a better overview of the status of the airways. This might contribute to recognizing early physiological impairment in smokers, perhaps as an alternative to the need to develop more expensive and complex tests.

Epidemiology and prevalence of COPD

The prevalence of COPD varies across countries; accurate estimates based on standardised population-based sampling of adults aged 40 and over in 12 sites in the burden of obstructive lung disease (BOLD) survey indicated an overall COPD prevalence (GOLD stage II or higher, FEV1 <80% predicted) (15) of 10.1% (SE 4.8). Prevalence increased with age and smoking history, but other factors were also thought to be important in explaining the variation. In the Australian BOLD survey conducted in six centres, prevalence was 7.5% (95% CI, 5.7-9.4%) overall, but was greater among those aged above 75 years at 29.2% (95% CI, 18.1-40.2%). The Australian survey showed large variations between centres the causes of which are being investigated (unpublished data).

Estimates of the population attributable fraction of tobacco smoking as a cause of COPD vary by age and population setting (18), although more recent estimates in those aged 30-69 years, 54% for men and 24% for women, are probably accurate and less than the widely quoted 80-90% in the 1984 US Surgeon General Report (19). Attributable fractions are higher in industrialized countries than developing countries and other risk factors are also important, including exposure to

biomass smoke, occupational exposures to dust and fumes, history of pulmonary tuberculosis, outdoor air pollution, and poor socioeconomic status (20) or chronic asthma (21). However smoking remains the most important cause of COPD in western countries. Around 50% of smokers eventually develop COPD, although the risk falls by about half following smoking cessation.

Diagnosis of COPD

As discussed previously, spirometry is accepted as the diagnostic test to assess airflow obstruction and classify severity of disease, based on specific cut points for FER (FEV1/FVC <0.7 after bronchodilator) and FEV1 (mild $\geq 80\%$ predicted, moderate 50-80%, severe 30-49% predicted, very severe <30% predicted). FEV1 normally decreases with age, and the rate of fall is an important spirometric indicator of disease progression in COPD. In healthy non-smoking adults the decrease is about 30 mL/year with an upper limit of about 50 mL/year; a decrease greater than this is considered abnormally rapid. There is debate on the use of a single fixed cut-off for FER to confirm the presence of airflow obstruction in COPD, because the lower limit of normal for FER decreases with age. Thus, this may misclassify some older patients as having COPD. Similarly, basing the classification of COPD on FEV1 as percentage predicted may misclassify patients especially the elderly and those in global initiative for chronic obstructive lung disease (GOLD) stages I and II. It has been proposed that classification should be based on a lower limit of normal (LLN) i.e., more than 1.64-SD below the predicted level (5th percentile) (28), although international guidelines still recommend use of the fixed FER for diagnosis.

Maximum flow achieved during forced expiration decreases progressively as lung volume falls and is most evident in the expiratory flow-volume curve where flow is plotted as a function of volume. Although flow and volume are complex biological signals, the curve is highly repeatable in both healthy and obstructed individuals and the shape of the curve can be helpful as it reflects the underlying mechanics limiting maximal flow. In healthy younger adults the shape of the flow-volume curve usually approximates a straight-sided triangle with maximum flows decreasing linearly with lung volume. In people with obstructive lung disease key physiologic features of the flow-volume curve are reduced expiratory flows in proportion to disease severity and the presence of a concavity in the descending limb; the latter indicating an abnormal decrease in maximal flow as lung volume falls.

Flow measurements derived from spirometry such as the forced expiratory flow over the middle half of the FVC (FEF25-75%) and forced expiratory flow at 75% of the FVC (FEF75%) may be more specific to small airway function, particularly in the presence of a normal FEV1, but they have not proved particularly helpful because they are dependent on the



Asthma Focus

measurement of FVC, lack the repeatability of FEV1, have a wide normal range, and are reduced in the presence of narrowing occurring in proximal airways.

COPD recognition and detection

However, in spite of spirometric standards for diagnosis, a high proportion of COPD in the community remains undiagnosed; estimates of non-diagnosis in the 1990's were 66% in the US to 78% in Spain. Underrecognition is related to the severity of airflow obstruction; 50% of those with FEV1 <40% predicted reported a physician diagnosis of COPD, but only 19% of those with FEV1 between 60-79% predicted in the Obstructive Lung Disease in Northern Sweden study. More recently, only 5.2% of BOLD population survey participants in Australia reported having been diagnosed with COPD compared to the 7.5% prevalence detected. Undetected COPD or asthma is common in primary care; over half those aged between 25-70 years in general practices in the Netherlands had symptoms or signs. There is also consistent evidence of misclassification of COPD in general practice. Substantial misclassification (31% and 42%) based on practice records COPD diagnosis was found in two studies in Australia. This probably relates to the diagnosis not being based on objective spirometry testing criteria.

Increased detection of COPD may result from a community-based screening programme; 27% of participants aged over 40 years had airflow obstruction based on FER <85% predicted in outpatient clinics in Poland. However such screening has not been widely implemented; a US Preventive Services Task Force assessment of the evidence did not recommend screening with spirometry and concluded with moderate certainty that there was no net benefit.

A more cost effective strategy using opportunistic case finding in primary care based on the presence of risk factors (age and smoking) and symptoms is recommended in the UK Update Guideline on COPD. A substantial amount of undiagnosed clinically significant COPD was demonstrated in the Health Survey for England 1995-6. In over half these cases of unrecognized COPD management guidelines recommend treatment, either with combination inhaled corticosteroid/long-acting beta agonist or anticholinergic inhaler to reduce hospitalisation and mortality, or pulmonary rehabilitation to improve quality of life. Case finding can be effective when conducted opportunistically for patients attending general practice for any reason, compared with only a small improvement for 'targeted' case finding using pre-attendance practice register searches and mail out invitations to selected patients.

In many health systems, primary care provides the most accessible and most frequently accessed health care and efforts to increase recognition and diagnosis of COPD have mainly focussed on general practice. Spirometry testing should focus on those at risk particularly from smoking; thus spirometry was able to detect unrecognised airflow obstruction

(FEV1 <80% predicted) in 22% of current smokers aged 35 to 70 years with at least one typical COPD symptom in the Netherlands. The proportion of COPD of at least GOLD grade II (FEV1 <80% predicted) in smokers aged over 40 in general practices varies, from 25% in a Canadian study to 47% in a study in Belgium, with only around a third in both already having a COPD diagnosis.

An alternative approach is to base spirometry testing on respiratory-relevant symptom screening using a questionnaire, with the cut-off score for subsequent spirometry chosen to maximise sensitivity and specificity. In this way, using a COPD screening questionnaire and a cut-off score of 17 or above (range, 0-40) in patients over 40 years attending general practice in Greece, the sensitivity for new COPD diagnosis was 93% but specificity was only 39%. Simple inexpensive hand-held spirometers are available for use in general practice; they display FEV1, forced expiratory volume in 6 seconds (FEV6) as a surrogate for FVC, and the ratio FEV1/FEV6. Applying a cut off ratio FEV1/FEV6 <0.7 after bronchodilator in the same study in Greek general practices, increased the specificity to 94% with sensitivity of 80% for COPD diagnosis.

A further refinement for identifying COPD in general practice is to combine a COPD symptom questionnaire with measurement of FEV1/FEV6 ratio. In the Greek study quoted above, the combination of the questionnaire with its high negative predictive value and the hand-held spirometer with its high positive predictive value had a sensitivity of 74% and specificity of 97% for COPD diagnosis, while the negative predictive value was 95% and positive predictive value was 82%. In a scenario when individuals at risk of COPD in primary care were screened with a handheld spirometer before full spirometry testing, a cut off point corresponding to FEV1/FEV6 <0.75 was found to offer optimal sensitivity (81%) and specificity (71%) for diagnosis in current and former smokers aged over 50 years. Linking symptom screening to case finding for COPD is ideal if the intention is to commence treatment in symptomatic individuals, but this approach is less suitable if the aim is to reduce end-organ disease.

Symptoms and a diagnosis of COPD

The place of symptoms in the diagnostic criteria for COPD has been debated and there is some inconsistency between GOLD and NICE guidelines, with NICE advising not diagnosing COPD in the absence of symptoms in patients with mild airflow obstruction (FER <0.7, FEV1 >80% predicted). However, there is substantial evidence that reported symptoms are unreliable for diagnosis, although in general the symptom burden in COPD increases with severity of airflow obstruction. There is wide variation in the degree of breathlessness, health status and exercise capacity within GOLD stages; thus even when airflow obstruction is severe in COPD, some people do not report symptoms or exercise limitation.



There is also under-presentation by patients with potential chronic respiratory disease who do not raise respiratory symptoms with their general practitioner; 46% of patients with spirometrically confirmed COPD had not paid a single visit for respiratory health problems during a 10-year observational study in the Netherlands. Patients may attribute their symptoms to ageing and attribute multicausal explanations that lessen the importance of obtaining a diagnosis. On the other hand, respiratory symptoms typical of COPD may be noted in practice records for long periods prior to diagnosis, with varying attitudes and degrees of vigilance among general practitioners to early diagnosis. Thus diagnosis of COPD may be delayed and indeed often does not occur until an acute exacerbation results in admission and hospital-based diagnosis.

Early diagnosis

Early diagnosis is a contentious issue, but it optimises the opportunities to prevent worsening of disease and prevention of comorbidities. Guidelines for COPD emphasise that it is a multi-system disease requiring a multidimensional approach to treatment. There is a strong emphasis on smoking cessation in both NICE and GOLD guidelines as the intervention with the greatest capacity to influence the natural history of COPD. Although a review in 2007 of randomised controlled studies on the value of spirometry itself as a motivational tool to increase smoking cessation was inconclusive, telling smokers their 'lung age' based on spirometry testing increased 12 months sustained quitting by over 7%, irrespective of the actual deficit in 'lung age'.

An increased risk of lung cancer in COPD was found in a long term US observational study in moderate or severe COPD (61) and in a case control study in lung cancer. The increased risk with COPD is present even when allowance is made for cigarette smoking history.

Similarly, the association of reduced FEV1 with increased overall mortality has been recognized in studies in nonsmokers and smokers, with the effect of reduced FEV1 independent of smoking history. The potential importance of the FVC was highlighted in a USA general population cohort without chronic respiratory diagnoses or persistent respiratory symptoms, in which survival was associated with higher FVC in both men and women after adjustment for

smoking and demographic factors. Such associations underlie the need for an earlier awareness of abnormality on spirometry as a part of

Antidepressants in late pregnancy are linked to respiratory disorder in newborns, study finds

The use of antidepressants during late pregnancy may be associated with a small increased risk for persistent pulmonary hypertension of the newborn, according to recent study findings.

Persistent pulmonary hypertension of the newborn is associated with substantial morbidity and mortality: 10% to 20% of affected infants will not survive, and infants who survive face serious long-term sequel including chronic lung disease, seizures, and neurodevelopmental problems due to both the hypoxemia and the aggressive treatments it often requires.

The cohort study included 3,789,330 pregnant women enrolled in Medicaid across 46 U.S. states and Washington, D.C, between 2000 and 2010 from 2 months or less after the date of last menstrual period through at least 1 month after delivery. The source cohort included only those diagnosed with depression.

The researchers compared women who used SSRIs within the 90 days before delivery vs. women who did not use the therapies. Primary outcome measure was the recorded diagnosis of persistent pulmonary hypertension within the first 30 days after delivery.

According to study results, 128,950 women filled at least one prescription for antidepressants late in pregnancy, of whom 102,179 used SSRIs and 26,771 used a non-SSRI. Compared with 31 per 10,000 infants exposed to antidepressants during the last 90 days of pregnancy who had pulmonary hypertension of the newborn, there were 20.8 per 10,000 infants not exposed to antidepressants during the last 90 days of pregnancy who had pulmonary hypertension of the newborn. The risk was higher among infants exposed to SSRIs (31.5 per 10,000 infants) and non-SSRIs (29.1 per 10,000 infants).

After restricting analysis to women with depression and adjusting for high-dimensional propensity score, the unadjusted OR for the associations between antidepressant use and pulmonary hypertension of the newborn was 1.51 (95% CI, 1.35-1.69) and 1.1 (95% CI, 0.94-1.29) for SSRIs. The OR for non-SSRIs was 1.4 (95% CI, 1.12-1.75) and 1.02 (95% CI, 0.77-1.35), respectively, according to the researchers.

The findings in the largest cohort studied to date, using advanced epidemiologic methods to mitigate confounding by the underlying psychiatric illness and its associated conditions and behaviours, suggest that the risk for pulmonary hypertension of the newborn associated with late pregnancy exposure to SSRI antidepressants - if present - is smaller than previous studies have reported.

Source: BMJ 2015;350:h2980

Adjunctive glucocorticoids for adults with severe community-acquired pneumonia

Adjunctive corticosteroids improve at least some outcomes for people with community-acquired pneumonia (CAP), according to results of a systematic review and meta-analysis. Among patients with severe community-acquired pneumonia and high inflammatory response, steroid-group patients were less likely to experience treatment failure than placebo-group patients.

In this trial, conducted at three teaching hospitals in Spain, investigators randomized adults with severe CAP and a high inflammatory response (C-reactive protein level >150 mg/L) to receive intravenous methylprednisolone 0.5 mg/kg or placebo every 12 hours for 5 days. Exclusion criteria included severe immunosuppression, nosocomial pneumonia, uncontrolled diabetes, H1N1 infection, and prior steroid treatment. The primary endpoint was treatment failure - a composite that included clinical outcomes (e.g., shock, mechanical ventilation, or death) and radiographic progression.

Of the 120 patients randomized between 2004 and 2012, 90 were in the intensive care unit on enrolment; 112 completed the study. A specific microbiologic diagnosis (most commonly *Streptococcus pneumoniae*) was made in 49 cases.

Steroid-group patients were significantly less likely than placebo-group patients to experience treatment failure (13% vs. 31%) or to show radiographic progression (2% vs. 15%). In-hospital mortality (10% and 15%) and causes of death were similar between groups. Patients with a persistently elevated inflammatory response on day 7 were more likely to have treatment failure and to die. Rates of adverse events, including hyperglycemia and acute kidney injury, were similar between groups.

For hospitalized patients with community-acquired pneumonia (CAP), glucocorticoids as adjunctive therapy to antibiotics have the potential to reduce the inflammatory response and decrease morbidity. A reduction in all-cause mortality was of borderline statistical significance (relative risk [RR] 0.67, 95% CI 0.45-1.01; risk difference 2.8 percent). Rates of mechanical ventilation and acute respiratory distress syndrome were decreased, as were time to clinical stability and duration of hospitalization; rates of hyperglycaemia requiring treatment increased. Clinicians should make the decision whether or not to give glucocorticoids on a case-by-case basis, especially in patients with an elevated risk of adverse effects. Limited evidence suggests that infections caused by certain pathogens (eg, influenza virus, *Aspergillus* spp) may be associated with worse outcomes in the setting of glucocorticoid use; given these concerns, adjunctive glucocorticoids should be avoided if one of these pathogens is detected.

Source: webmd HealthDay

a general health screening approach, such as was taken in cardiovascular disease to reduce the high burden of mortality that existed 40 years ago.

Value of current diagnostic tools for COPD: spirometry

Spirometry is a safe, practical and reproducible maximum breathing test that can be used in primary care to objectively determine the ventilatory capacity of the lungs. As already emphasised earlier in this article, it is the 'gold standard' for detecting and quantifying airflow obstruction and as discussed, is the core component of clinical guidelines for the diagnosis and management of COPD. The test is relatively quick to perform, well tolerated by most patients and the results are immediately available to clinician. It is important to appreciate that the clinical value of spirometry is critically dependent on the correct operation and accuracy of the spirometer, performance of the correct maximal breathing manoeuvre, selection of the best test results to use and correct interpretation. When a trained and experienced operator using modern equipment conducts the test, at least 90% of adults are able to provide acceptable and repeatable results. In the primary care setting the rate is lower but can still be reasonable at about 80%, especially when the spirometer grades each test and provides feedback relating to test quality.

Development of spirometry

A spirometer is a medical device that allows measurement of how much air is expelled and how quickly the lungs can be emptied, in a maximal expiration from full inflation. Modern spirometry has its origins in the 1840's when the English surgeon, John Hutchinson, developed the spirometer and described the measurement of slow vital capacity as a means of detecting lung disease. One hundred years later Tiffeneau and Pinelli from France revolutionised spirometry by describing the forced expiratory timed spirogram and introducing an obstructive index, the ratio FEV1/inspiratory vital capacity (IVC) which is still used today, albeit with IVC most commonly replaced with FVC or expiratory vital capacity. It was only a few years later in 1960 that the American physiologists, Fry and Hyatt, in a landmark study of lung mechanics, replotted the data contained in the timed spirogram in the form of the flow-volume curve which is now universally accepted as the preferred method of graphically displaying spirometric data. The flow-volume curve is now available in almost all commercially available spirometers and is displayed in realtime as the patient performs the test.

Asthma Focus



Modern spirometers

Almost all modern spirometers utilise a sensitive real-time flow sensor to directly measure respired flow and obtain volume by electronic or numerical integration. Manual volume-displacement spirometers are still in limited use, especially in primary care, such as the iconic wedge bellows Vitalograph which over many decades has played a very significant role in popularising the measurement and application of spirometry beyond the expert laboratory, but this genre of spirometer usually lacks portability, is difficult to clean and disinfect, can be difficult to calibrate and requires spirometric variables to be calculated manually and does not produce the flow-volume curve.

There are many spirometers on the market today and most are robust, portable, accurate and reliable and specifically designed for use in either a lung function laboratory or a physician's office. Most, if not all, modern spirometers meet minimum international performance standards and validation procedures that were developed jointly by the American Thoracic Society and European Respiratory Society. These include meeting accuracy requirements for volume, flow and time signals using specifically developed test signals, and applying the back-extrapolation technique to identify both sluggish starts to the blow and the zero time point from which timed volumes such as FEV1 are calculated. Modern spirometers also have the added advantages of infection control, automatic calculation of all lung function indices including correction for temperature, pressure and water-saturation conditions. Many will also provide immediate computer-generated feedback to the operator on the test quality and repeatability as well as real-time graphical display of the spirogram and flow-volume curve, will select the best results to report, calculate normal reference values including the lower limit of normal and can automatically upload results to medical records.

Primary care spirometry

Spirometry is commonly performed outside the lung function laboratory. A survey of primary care practices in Australia found that 64% owned a spirometer with almost 70% performing at least one test per week mainly for the diagnosis and management of asthma and COPD. The high spirometer ownership was not surprising given that a large number of patients with lung disease are first seen and subsequently managed in primary care.

Opinion is divided as to whether the quality of spirometry performed outside expert laboratories meets adequate minimum standards with the potential for high rates of misclassification, especially when the results are near the lower limit of normal. The measurement of spirometry requires a motivated and enthusiastic operator to coach the patient to perform a number of very rigorous maximally forced and

sustained breathing manoeuvres. It is not surprising therefore that unlike most other medical tests such as the measurement of blood pressure and the electrocardiogram, the quality of spirometry tests are crucially dependent on the operator and cooperation of the patient and thus spirometry performed in primary care is often of poor quality. Although the key to obtaining quality spirometry is attending a comprehensive training course, the importance of testing experience cannot be overstated and may well be the most important factor.

The concave pattern on flow-volume curve

Current guideline criteria for airway obstruction and its severity essentially rely on just two variables FEV1 and FVC, and their ratio the FER. Although these variables have played an important role in developing our understanding of the mechanisms and functional effects of COPD, we have emphasised that they are relatively insensitive to early obstructive small airway pathology, because these cause FVC to fall first with initial preservation of the FER. Spirometry has thus been of limited use as a screening tool for early disease; this is disappointing as it is the most practical and widely performed test of lung health and should therefore be ideal to screen for early disease. We present a case that relying solely on the FEV1 and FER potentially misses information contained in the whole flow-volume curve, particularly the concave pattern, which may provide greater sensitivity in detecting and monitoring early disease.

The development of concavity in the descending limb of the maximum expiratory flow-volume curve is a recognised feature of airflow obstruction, with greater concavity reflecting increased obstruction, and the first indication of a concavity is frequently seen in the tail of the curve. This is explicitly acknowledged in the ATS/ERS statement on the interpretation of lung function, but has largely been ignored in practice because none of the measurements taken currently to reflect this concavity are robust enough.

The functional information provided by the FEV1 is necessarily limited to the first second of the forced expiratory manoeuvre when the lung is relatively fully inflated and the small airways exposed to significant distending forces. This means that in older people with a normal FER, as much as 40% of the flow-volume curve is not assessed, all in the terminal portion of the curve, and a greater proportion in people with airflow obstruction. In contrast, the concave pattern seen in people with airflow obstruction is not limited to the first second but often extends over most of the curve, reflecting a global pattern of airway dysfunction. In early airflow obstruction, when the FEV1 is normal, a concavity is often present and may well be mostly confined to the terminal portion of the curve where lung volume is relatively low and the distending forces on the small airways are significantly reduced, resulting in a higher peripheral airway resistance and non-uniform emptying in peripheral lung regions.



Asthma Focus

It is notable that the latter may well be the major spirometric defect signalling early disease and requires better quantitative assessment.

The concave pattern develops when lung compartments have widely differing expiratory time constants causing regional inhomogeneity as is certainly the case in obstructive lung disease with peripheral increase in airway resistances, with the slowest emptying compartments contributing disproportionately to flows near residual volume, resulting in a curve with the familiar exaggerated 'tail'. It is not surprising, therefore, that even though the underlying mechanics determining FEV1 and the concave pattern overlap, they are not necessarily equivalently strong physiological signals at different disease stages. They may however be quite complementary, not only in assessing airflow obstruction overall but especially in detecting early obstructive small airway disease.

It seems reasonable that to detect and assess early disease we need a method that is sensitive to inhomogeneous airway emptying because this almost certainly precedes the development of the more advanced obstruction for which we use currently the standard FER. Highly sophisticated technology is currently being developed to measure this inhomogeneous lung emptying, but it could well be that much of this information is already available in the expiratory flow-volume curve if only it can be harnessed.

Strong evidence that a concavity confined in the terminal portion of the curve is most likely to be associated with small airways dysfunction came from further studies that compared flow-volume curves obtained breathing gases of widely differing gas density which showed that maximal flows near the terminal portion of the flow-volume curve predominantly reflect small airway function. This is also consistent with studies using wave speed mechanics and the equal pressure point theory which predicts that the flow-limiting segment developed during forced expiration moves peripherally into progressively smaller airways as lung volume falls and especially when peripheral airway resistance increases.

The clinical value of quantifying concavity has been underappreciated although demonstrated spirometrically in different populations. The study by Kraan et al. was of particular interest as it provided strong evidence that although the reduction in FEV1 and the degree of concavity are related, they do not necessarily measure the same things; for example they were differentially affected by bronchodilator and anti-inflammatory treatment. Schachter et al. showed that although cotton workers had abnormal spirometry, the concave pattern was only present in current cigarette smokers. Another study showed the degree of concavity was greater in those with a smoking history and people with breathlessness and wheezes.

New indices to quantify concavity

Visual assessment of concavity in the flow-volume curve is highly subjective and cannot reliably be used to assess an abnormal degree of concavity. What is needed is a practical and easily understood numerical index to quantify concavity with clearly defined limits of normal. Although a number of methods have been described they are complex or difficult to apply routinely and none has been incorporated into commercial spirometry software or clinical guidelines.

However, we describe two indices for estimating concavity (global and peripheral) with preliminary data comparing these with conventional spirometric variables, in a randomly selected population of adults aged >40 years in Australia. The global index is based on FEF50% and quantifies concavity that usually involves the entire descending limb, whilst the peripheral index is based on the FEF75% and independently quantifies concavity present near the terminal portion of the curve. The degree of concavity is obtained by calculating the percentage decrease of the measured flows from the corresponding idealised reference flows.

Conclusions

The standard respiratory function test for case detection of COPD is spirometry, with the criterion for diagnosis defined in guidelines being based on FER and the severity being based on FEV1. However, using this approach is poor at detecting early disease in the small airways. Improved, although more complex, tests are being developed to recognise such early cases but we have shown that by using all the information available from the spirometric expiratory flow-volume curve, and especially by quantifying the degree of concavity, that this may be in itself more sensitive and specific for small airways disease. However, even the current means of diagnosing relatively more severe disease that is detectable by the FER threshold is poorly taken up in primary care, despite the benefits that could be achieved with smoking cessation and pharmacological and non-pharmacological interventions to improve patients' well-being. The reasons are not completely understood but include attitudes of both doctors and patients to COPD. The potential importance of detecting early fixed airway obstruction for prevention of lung cancer and nonrespiratory end-organ disease also needs to be better highlighted in public health campaigns.

Ref: www.jthoracdis.com J Thorac Dis 2014;6(11):1557-1569

Asthma Focus



Montene™

Montelukast 4 mg, 5 mg & 10 mg tablet

Once daily to prevent
asthma & allergy symptoms

- Once daily to prevent asthma symptoms
- An effective 1st line asthma controller
- Works from the first day of therapy
- Prevention of exercise-induced bronchoconstriction

Ticamet®

100 & 250 Cozycap,
125 & 250 HFA MDI 120 puffs

Salmeterol & Fluticasone propionate

An evolution in asthma care

- Provides long-term protection
- Increases patients' compliance
- Ensures no chance of skipping one drug

Since 1958



www.squarepharma.com.bd

[facebook.com/SquarePharmaLtd](https://www.facebook.com/SquarePharmaLtd)

twitter.com/SquarePharmaBD



Congratulations!!!

Editorial Note

The Winners of **Asthma Focus** Quiz Competition

Vol. 11 No. 2

Dr. Shamsul Alam

MBBS, Medical officer, Talim Nagar USC
Sujanagar, Pabna

Dr. Bolai Chandra Sarkar

MBBS, FCPS, Asst. Professor, Medicine
RMCH, Rajshahi

Dr. Md. Rafiqul Alam

MBBS, FCPS, MD (Chest)
Associate Professor, Medicine, BSMMU
Dhaka

Dr. Shamima Akhter Kakoli

MBBS, FCPS, Medical Officer
Memon Hospital, Sadarghat
Chittagong

Dr. Mousumi Khan

MBBS, MS (Part-1), IMO, Pediatric indoor
Kurmitola General Hospital
Dhaka



Dear Doctor,

We are happy to present you the 3rd issue of "Asthma Focus" Newsletter, 2015. In this issue we have concentrated 'Diagnosis and early detection of COPD using spirometry'. We hope you will enjoy reading the publication!

We appreciate your comments and queries. Please participate in Quiz competition & win prizes.

Editorial Board

Dr. Omar Akramur Rab, MBBS, FCGP, FIAGP
Ahmed Kamrul Alam, M. Pharm, MBA
Faisal Jahidur Rahman, M. Pharm

Executive Editor

Md. Imran Ali, M. Pharm
imran.ali@squaregroup.com